

# Are there links between the surge in DVT cases and COVID-19?

Sonika Tatipalli

## **Abstract**

In this past year, there has been a large increase in the number of deep vein thrombosis cases. A significant potential cause of this could be the COVID-19 pandemic. In fact, several in-depth studies prove how the incidence rates of DVT in the general population are remarkably lower than the incidence rate in COVID-19 patients. Additionally, COVID-19 induces a hypercoagulable state, triggering thrombotic episodes. Analyzing the overlaps of the risk factors of both these conditions and the specific anticoagulant thromboprophylaxis prevention of thrombosis in COVID-19 patients once again highlights how there seems to be a strong link between COVID-19 and the recent surge of DVT cases.

## Introduction

- COVID-19 has been present for nearly 1.5 years now, and the effects of this pandemic are innumerable.
- Yet another potential effect of COVID-19 is the increase in the number of Deep Vein Thrombosis (DVT) cases. Over the course of this past year, a multifold number of DVT cases are being reported compared to just a few years ago.
- This project aims to find a potential link between the surge in DVT cases and the ongoing COVID-19 pandemic.
- Methodology: Literature Search: Pubmed
  - Key Words: Covid-19, Thrombosis risk factors, Covid-19 patients at higher risk of thrombosis, Venous thrombosis, DVT, Incidence rates

# **Epidemiology**

- SARS-CoV-2 virus started in Wuhan, China in 2019
- 175 million cases and nearly 4 million deaths around the world
- An airborne disease, causing it to spread rapidly to anyone an infected person may contact
- Preventive techniques that evolved include using disinfectants, staying masked, and keeping a six-feet distance between people.

## **Statistics**

After the COVID-19 outbreak, the number of reported DVT cases increased significantly. At a specific hospital, a study shows that in mid-2019, the occurrence of DVT was 0.017%. Just a year later, this went up to 0.084%.

- 1. Hundreds of COVID-19 patients
  - 11% of patients developed DVT
  - 14% of critical patients developed DVT

- 2. COVID-19 patients who took a venous ultrasound in a specific hospital:
  - Over one-third of the developed DVT
- 3. Hospitalized COVID-19 and hospitalized non-COVID-19 patients:
  - 16% of COVID-19 patients developed DVT
- 4. & 5. General Population (10,000 & 100,000 people)
  - Only 0.5% of these populations developed DVT

## Pathophysiology/Mechanisms Of COVID-19

Membrane glycoprotein (M) SARS-CoV2 spike glycoprotein (S) full length

Figure 1: SarsCoV-2: single strand RNA surrounded with several spike proteins Mechanism of entry of COVID-19:


- Spike proteins located on the outer surface of the virus bind to angiotensin converting enzyme-2 (ACE2) receptors and prevents their function.
- This leads to an inflammatory immune response causing a hypercoagulable state
- Triggers a coagulation cascade.

Pathophysiology/Mechanisms
Of DVT

Cellular RNA Activated platelet Bacteria Monocyte MV Activate endothelial

 DVT is a type of venous thromboembolism: blood clot occurs in a vein

- Venous clots are created mostly due to fibrin
- Formed through coagulation cascade,
   which includes the extrinsic, intrinsic, and



**Figure 2: Coagulation Cascade** 

## **Risk Factors**

#### **Thrombosis**

- Age
- Pregnancy
- Family history of clots
- Injury or surgery to veins
- Long periods of immobility
- Diabetes
- Obesity
- Hypoxia
- Hypertension

#### COVID-19

- Immunodeficiencies
- Old age
- Being a male
- Hypertension
- Diabetes
- Obesity
- Chronic lung diseases
- Heart, liver and kidney diseases
- Tumors
- Pregnancy

## **Overlaps in Risk Factors**

- Age
- Pregnancy
- Diabetes
- Obesity
- Hypertension

Several of the COVID-19 risk factors overlap with DVT risk factors. Therefore, these increase the chance of both the conditions. This shows how many patients with COVID-19 are likely to also develop thrombosis and justifies the statistics regarding this.

## Symptoms of COVID-19

- Fever
- Cough
- Shortness of breath
- Muscle pains
- Headache
- Nausea
- Chest pain

- Shortness of breath symptom → less oxygen
   rich blood → hypoxia: a risk factor of thrombosis
- Critical COVID-19 patients in the Intensive Care Unit (ICU) are less likely to move around → a significant risk factor of thrombosis is a lack of movement → those in the ICU with COVID-19 have a higher chance of developing blood clots compared to a healthy person due to this situation

# **Therapies**

- Anticoagulant thromboprophylaxis is recommended for prevention of thrombosis in COVID-19 patients
- If there are no contraindications, low molecular weight heparin (LMWH) is more recommended than unfractionated heparin (UFH)
- UFH is more recommended than direct oral anticoagulants (DOACs)
- For hospitalized COVID-19 patients with DVT or PE, adjusted LMWH or UFH is most recommended.
- Outpatient COVID-19 patients are recommended to use apixaban, dabigatran, rivaroxaban or edoxaban, but DOACs are usually not a recommended therapy for COVID-19 patients.

## Conclusion

- To conclude, there are several connections between COVID-19 and DVT in patients. Therefore, I believe there is a strong link between the surge in DVT cases and the COVID-19 pandemic.
- Some important things to consider in the future would be to further analyze more studies and statistics and look into other links between these conditions.
- Acknowledgements: I would love to thank Dr. Mousa for mentoring me through this project. I would also like to thank Dr. Laddu and the GTF Board for presenting me with this amazing opportunity

# Bibliography

- Karaali E, Ciloglu O, Demirturk O, Keklikcioglu B, Akcay I, Ekiz T. <u>Increased deep vein thrombosis cases during the COVID-19 quarantine</u>. *Phlebology*. 2020; 36(2):114-118
- Pascarella G, Strumia A, Piliego C, Bruno F, Buono RD, Costa F, Scarlata S, Agro FE. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020; 288(2):192-206
- Gao Y, Ding M, Dong X, Zhang J, Azkur A, Azkur D, Gan H, Sun Y, Fu W, Li W, Liang H, Cao Y, Gao H, Bruggen M, van de Veen W, Sokolowska M, Akdis M, Akdis C. <u>Risk factors for severe and critically ill COVID-19 patients: A review.</u> Allergy. 2021; 76(2):428-455.
- Thachil J. <u>Hypoxia-An overlooked trigger for thrombosis in COVID-19 and other critically ill patients.</u> *J Thromb Haemost.* 2020; 18(11):3109-3110.
- Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M, Ashraf MZ.
  <u>Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia.</u> Proc Natl Acad Sci U S A. 2017;114(18):4763-4768.
- Khan SA, Logan P, Asokan A, Handford C, Rajgor HD, Khadabadi NA, Moores T, Targett J. <u>The incidence of venous thromboembolism in total joint replacement during COVID-19 pandemic.</u> Bone Jt Open. 2020;1(12):751-756.
- Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, Le Gal G, Rali P, Wells P. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest, 2020, 158(3):1143-1163.

# Bibliography, Cont.

- Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012; 122(7):2331-6.
- Pollard CA, Morran MP, Nestor-Kalinoski AL. <u>The COVID-19 pandemic: a global health crisis</u>. *Physiol Genomics*. 2020; 52(11):549-557.
- Ieradi AM, Coppola A, Fusco S, Stellato E, Aliberti S, Andrisani MC, Vespro V, Arrichello A, Panigada M, Monzani V, Grasselli G, Venturini M, Rehani B, Peyvandi F, Pesenti A, Blasi F, Carrafiello. <u>Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?</u> *J Ultrasound.* 2021; 24(2):165-173.
- Yu Y, Tu J, Lei B, Shu H, Zou X, Li R, Huang C, Qu Y, Shang Y. <u>Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients</u>. Clin Appl Thromb Hemost. 2021; 26: 1076029620953217.
- Smilowitz NR, Subashchandran V, Yuriditsky E, Horowitz JM, Reynolds HR, Hochman JS, Berger JS.
  <u>Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19</u>. Am Heart J. 2021; 231:93-95.
- Anderson Jr FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. <u>A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study</u>. *Arch Intern Med.* 1991; 151(5):933-8.
- Fowkes FJI, Price JF, Fowkes FGR. <u>Incidence of diagnosed deep vein thrombosis in the general population:</u> <u>systematic review</u>. Eur J Vasc Endovasc Surg. 2003; 25(1):1-5.